Lưu trữ — US — techcrunch
Biotech Nephrogen combines AI and gene therapy to reverse kidney disease — checkit out at TechCrunch Disrupt 2025
Biotech startup Nephrogen, founded by Demetri Maxim, combines AI and gene therapy to tackle Polycystic Kidney Disease (PKD). Following an impactful study in 2021, the company has developed a delivery mechanism that is significantly more effective than current FDA-approved solutions. Nephrogen is a finalist at TechCrunch Disrupt 2025, with plans to initiate clinical trials for its therapy by 2027 while raising $4 million in seed funding.
Điểm chính
- Demetri Maxim's mother suffered from kidney failure and received a transplant, highlighting a personal connection to kidney disease.
- Maxim inherited Polycystic Kidney Disease (PKD) and has been driven to find a cure.
- Inspired by a 2021 study showing PKD could be reversible in mice using CRISPR, he founded Nephrogen in 2022.
- Nephrogen's novel delivery system is 100 times more efficient than existing products, aiming to effectively transport gene therapies.
- The company is raising $4 million for clinical trials expected to begin in 2027.
Vì sao quan trọng
- Knee disease has a high prevalence in the U.S., with about 1 in 7 affected by Chronic Kidney Disease (CKD).
- Advancements in gene editing and AI in healthcare represent significant 2025 IT trends, leading to potential breakthroughs in treatment.
- The focus on startup innovation and biotechnology is aligning with global health challenges, spotlighting the significance of platforms like TechCrunch Disrupt.
Nephrogen's innovative approach combines cutting-edge AI and gene therapy, positioning it at the forefront of medical advancements aimed at reversing kidney disease, which could vastly improve quality of life for many suffering from PKD.